Business Context and Reporting Period
This Form 8-K Current Report was filed by Arrowhead Pharmaceuticals, Inc. on June 12, 2026. The filing discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation.
- Director Sign-on Grant: Restricted stock units valued at $887,000.
- Vesting Schedule: Three years.
Material Changes
The material change reported is the addition of Dr. Matt Cohen, M.D., M.B.A., to the Board of Directors, effective June 12, 2026. Dr. Cohen brings over 25 years of experience in healthcare investing and portfolio management, most recently serving as Managing Director at Vida Ventures and previously as a lead growth-focused healthcare investor at JP Morgan Asset Management since 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, risks, contingencies, or unusual items. It strictly addresses the appointment and compensation of the new director.
Investor Verification Checklist
- Verify the total number of directors on the Board following this appointment.
- Review the "Director Compensation" section of the definitive Proxy Statement filed on January 27, 2026, for details on standard non-employee director compensation.
- Confirm the vesting terms and potential dilution impact of the $887,000 restricted stock unit grant.